Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare leukodystrophy characterized by cerebral edema, subcortical cysts, myelin vacuolation, and astrocyte swelling. Patients show macrocephaly and progressive cognitive and motor impairment featuring ataxia, spasticity, and epilepsy. This disease belongs to astrocytopathies, a group of leukodystrophies distinguished by progressive cystic degeneration of myelin and caused by a primary astrocyte dysfunction. The pathology is mainly associated with mutations in the gene encoding MLC1, an astrocyte-specific protein highly expressed at the astrocyte-astrocyte junctions and the perivascular astrocytic end-feet. Although the precise function of MLC1 remains unclear, several studies have demonstrated its critical role in regulating astrocyte volume, proliferation, and activation in response to injurious stimuli. Using astrocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs), we recently showed that MLC1 mutations lead to astrocyte maturation defects. Given the important roles of astrocytes during neurodevelopment, including the regulation of neurogenesis, synaptogenesis, oligodendrocyte differentiation, myelination, and blood-brain barrier formation, we hypothesized that the resulting dysfunctional astrocytes may be incapable of properly supporting brain development. In this study, we generated iPSC-derived brain organoids to investigate whether impaired astrocyte maturation also affects oligodendrocyte differentiation/maturation, potentially contributing to the myelin abnormalities observed in MLC. Brain organoids were generated from two healthy controls and four MLC patients and analyzed at days 50 and 70 of differentiation using Western blotting, quantitative PCR, and immunofluorescence to assess the expression of astrocytic, oligodendrocytic, and neuronal markers. Both control and MLC-derived organoids successfully developed the major brain cellular populations. However, MLC organoids exhibited reduced expression of mature astrocyte markers at both time points compared to controls. In addition, immunofluorescence at day 50 revealed a marked downregulation of oligodendrocyte markers in MLC organoids. These findings confirm impaired terminal differentiation of MLC astrocytes and suggest that this dysfunction may negatively affect oligodendrocyte development, a process essential for proper myelination. iPSC-derived brain organoids therefore represent a valuable model to study MLC pathophysiology and a robust platform for future therapeutic screening.
DEVELOPMENT OF BRAIN ORGANOIDS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS FOR STUDYING THE RARE LEUKODYSTROPHY MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS / Caprini, E.S., Lanciotti, A., Brignone, M.S., Rosicarelli, B., Sposito, S., Alfieri, L., Veroni, C., Meloni, C., Santia, L., Scipioni, A., Nicita, F., Bertini, E., Serafini, B., Ambrosini, E.. - (2026). (Phd Day Academic Year 2025-2026 of National Institute of Health Istituto Superiore di Sanità ).
DEVELOPMENT OF BRAIN ORGANOIDS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS FOR STUDYING THE RARE LEUKODYSTROPHY MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS
Elena Sofia Caprini;Maria Stefania Brignone;Sara Sposito;Chiara Meloni;
2026
Abstract
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare leukodystrophy characterized by cerebral edema, subcortical cysts, myelin vacuolation, and astrocyte swelling. Patients show macrocephaly and progressive cognitive and motor impairment featuring ataxia, spasticity, and epilepsy. This disease belongs to astrocytopathies, a group of leukodystrophies distinguished by progressive cystic degeneration of myelin and caused by a primary astrocyte dysfunction. The pathology is mainly associated with mutations in the gene encoding MLC1, an astrocyte-specific protein highly expressed at the astrocyte-astrocyte junctions and the perivascular astrocytic end-feet. Although the precise function of MLC1 remains unclear, several studies have demonstrated its critical role in regulating astrocyte volume, proliferation, and activation in response to injurious stimuli. Using astrocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs), we recently showed that MLC1 mutations lead to astrocyte maturation defects. Given the important roles of astrocytes during neurodevelopment, including the regulation of neurogenesis, synaptogenesis, oligodendrocyte differentiation, myelination, and blood-brain barrier formation, we hypothesized that the resulting dysfunctional astrocytes may be incapable of properly supporting brain development. In this study, we generated iPSC-derived brain organoids to investigate whether impaired astrocyte maturation also affects oligodendrocyte differentiation/maturation, potentially contributing to the myelin abnormalities observed in MLC. Brain organoids were generated from two healthy controls and four MLC patients and analyzed at days 50 and 70 of differentiation using Western blotting, quantitative PCR, and immunofluorescence to assess the expression of astrocytic, oligodendrocytic, and neuronal markers. Both control and MLC-derived organoids successfully developed the major brain cellular populations. However, MLC organoids exhibited reduced expression of mature astrocyte markers at both time points compared to controls. In addition, immunofluorescence at day 50 revealed a marked downregulation of oligodendrocyte markers in MLC organoids. These findings confirm impaired terminal differentiation of MLC astrocytes and suggest that this dysfunction may negatively affect oligodendrocyte development, a process essential for proper myelination. iPSC-derived brain organoids therefore represent a valuable model to study MLC pathophysiology and a robust platform for future therapeutic screening.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


